Advertisement
Telegram ads for your business · TCA Media
RUUZEN
Advertisement
Telegram ads for your business · TCA Media
CBU ratesUSD 12 010,45EUR 13 200,69RUB 145,64Wednesday, 18 November 2026
Technology

Demis Hassabis's Company Raises $5 Billion for AI Drug Development

Isomorphic Labs, founded by former Google DeepMind head Demis Hassabis, has raised $5 billion in a Series C funding round. The funds will be directed toward developing drugs using AI.

cnbc.com

On Tuesday, Isomorphic Labs announced it had raised $5 billion. The round was jointly led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz; Alphabet, Google's parent company, also became an investor.

The funding followed approximately three and a half months after Hassabis stepped down as CEO of DeepMind. He continues to lead Isomorphic Labs, which was spun off from DeepMind in 2021.

The startup is developing its own AI-based drug design system and a portfolio of therapeutic candidates. According to Hassabis, the new funds will enable the creation of foundational biological models, deeper study of systemic diseases, and the advancement of the first programs toward clinical trials.

In 2026, drug discovery startups raised $23.2 billion—a record figure, according to the Dealroom platform. In May, Isomorphic Labs raised $2.1 billion in a Series B round. In April, OpenAI partnered with Novo Nordisk, and in June, Anthropic announced the launch of an AI-driven drug discovery program.

Advertisement
Telegram ads for your business · TCA Media